Accelerate New York Seed Fund

Cress Health develops digital platforms to enhance individual and organizational mental wellness. Its core offering is a healthcare platform that helps users track their feelings daily, connect with peers, share experiences, and gain insights through personalized reports.

Fuell is a manufacturer of premium electric mobility solutions aimed at providing alternatives to traditional car transportation in urban environments. The company focuses on developing e-vehicles that prioritize safety and advanced technology, tailored specifically to meet the needs of urban riders. By combining the expertise of its founders, Fuell creates an innovative riding experience that enhances urban mobility. In addition to its electric vehicles, Fuell offers digital services designed to enrich the overall experience of navigating cities, positioning itself as a leader in the evolution of urban transportation.

Qunnect develops quantum networking hardware and components that enable secure communication for distributed information networks. It designs field-deployable devices that transmit, store, and receive quantum information using photons to communicate and atoms to store or process data, supporting scalable, quantum-secure networks with real-time threat detection. The company focuses on quantum memories and quantum sources to enable future information networks and quantum computing, and provides infrastructure for quantum cryptography, networks, sensors, metrology, and imaging. Headquartered in Stony Brook, New York, Qunnect aims to bring practical quantum information technology to enterprise and government networks by delivering room-temperature hardware suitable for real-world deployment.

Goldilocks Therapeutics is a biotechnology company founded in 2018 and based in Bedford, New York. The company focuses on developing preventative treatments for acute kidney injury, polycystic kidney disease, and other renal conditions. Goldilocks Therapeutics utilizes proprietary mesoscale nanoparticles to specifically target therapeutic payloads to the renal tubule epithelium, allowing for sustained-release delivery of medications. This innovative approach aims to enhance treatment efficacy and improve the lives of patients suffering from kidney-related ailments.

CalmiGo is a company that develops a portable, drug-free medical device aimed at providing immediate relief from emotional and mental distress. The device utilizes advanced technology to help users manage moments of anxiety, stress, and distress by regulating their breathing patterns and stimulating their senses. This innovative solution is designed to be accessible to individuals of all ages and varying technical abilities, allowing them to address anxiety-related issues effectively, regardless of their location. By focusing on a natural approach, CalmiGo offers a convenient and immediate alternative for those seeking relief without the use of medication.

HashLynx designs and develops a platform for trade matching and settlement in the capital markets. Founded in 2018 and based in Middletown, New York, the company uses blockchain solutions and smart contract technology to provide an open-architecture platform that supports trading and settlement while integrating with legacy loan systems, enabling clients to reduce the time and cost of syndicated lending transactions and improve efficiency and transparency in capital markets.

Aspisafe Solutions is a medical device company specializing in the development of feeding tubes and related products. Its flagship product is a novel nasogastric tube designed to prevent stomach reflux, thereby reducing the risk of pneumonia.

Toggle is a United States-based company that specializes in robotics as a service (RaaS) for the construction industry. It focuses on automating the assembly of rebar cages for reinforced concrete applications, enhancing efficiency and precision in construction processes. Toggle's offerings include two-arm robotic platforms and proprietary jig designs capable of constructing various shapes directly from computer blueprints. In addition to its core services, the company also provides pre-assembly solutions, contributing to the advancement of robotics and automation in the construction sector.

TargaGenix, Inc., established in 2013 and headquartered in Stony Brook, New York, specializes in developing innovative compounds targeting drug-resistant tumors and cancer stem cells. Its flagship product, SBT-1214, has demonstrated promising results in preclinical models of colon, pancreatic, prostate, breast, and lung cancers, showing the ability to eliminate tumors entirely. Furthermore, SBT-1214 effectively downregulates "stemness" gene expression and kills cancer stem cells. Through chemical modifications and a novel fatty-acid based nanoemulsion formulation, the drug's pharmacokinetics, pharmacodynamics, and toxicity profile have been enhanced.

EpiVax Oncology is a biotechnology company focused on developing personalized immunotherapies for cancer treatment. Based in New York, the company specializes in precision cancer mutanome-directed and neo-epitope therapies, utilizing advanced immuno-oncology and neoantigen discovery solutions. EpiVax Oncology's platform relies on optimal neo-epitopes selected through proprietary, validated predictive algorithms to address unmet medical needs that current cancer therapeutic approaches do not adequately cover. The company was established in 2017 with the goal of providing innovative clinical research and development platforms for various types of precision cancer immunotherapies.

Concarlo Therapeutics is a preclinical-stage oncology company developing transformative therapeutics targeting drug-resistant cancers. The company focuses on therapies that target p27, inhibiting CDK4/CDK6 and CDK2 to kill tumor cells rather than just stopping their growth. Concarlo aims to create new treatments for various advanced and drug-resistant cancers.

Frenzy Labs, Inc. is a technology company that specializes in developing a visual search application platform to enhance image monetization for websites. Founded in 2017 and based in Marina Del Rey, California, Frenzy utilizes deep learning algorithms and computer vision to analyze website images, accurately identifying brands and products even in complex visual scenes without logos. The company offers various solutions, including self-labeling image technology that significantly reduces the need for manual labeling, thereby improving efficiency in managing image datasets. Frenzy's products include Fetch, a content monetization plugin tailored for fashion bloggers, and Frenzy Enterprise Solutions, which provides automated catalog management and precise image search capabilities for e-commerce platforms. By enabling users to seamlessly monetize their site images, Frenzy helps streamline the online shopping experience while minimizing the time and effort required to identify products.

Mirow LLC is a New York-based company founded in 2016 that specializes in manufacturing smart mirrors for fitting rooms, designed to enhance the retail experience. These interactive mirrors utilize touch technology and sensors to identify customer preferences, offering personalized recommendations, information on discounts, and automated assistance. Customers can easily call for sales support or request items in different sizes or colors directly from the fitting room. Mirow's innovative approach not only improves the quality of service but also provides retailers with valuable insights into customer behavior and preferences. The company has gained recognition in the retail and hospitality sectors and is expanding its presence in both the US and EU markets, serving a range of top-tier brands.

Digitouch Health is a medical device company based in Valhalla, New York, specializing in the development of a smartphone device that enables users to measure and track their blood pressure. The device utilizes advanced algorithm-enabled technology and oscillometry to provide accurate blood pressure readings without the need for calibration. It facilitates the monitoring of hypertension and allows for the seamless transmission of data to electronic health records, thereby enhancing patient convenience and ensuring clinical accuracy. By collaborating with healthcare practitioners, Digitouch Health aims to support individuals in managing their cardiovascular health, ultimately contributing to longer and healthier lives.

Bioharmony Therapeutics, Inc. is a biotechnology company focused on developing lysin-based antimicrobial therapeutics specifically designed to combat multi-drug resistant Gram-negative bacterial infections. Incorporated in 2016 and headquartered in New York, Bioharmony Therapeutics specializes in creating innovative treatments that target skin infections caused by pathogens such as Acinetobacter baumannii. Their therapeutics work by disrupting the bacterial cell wall, offering potential solutions for serious conditions like hospital-acquired pneumonia and critical blood or wound infections. Through its advancements in bacteriophage technology, the company aims to provide effective treatments for patients facing the challenges of antibiotic resistance.

DepYmed is a pharmaceutical company based in Cold Spring Harbor, New York, focused on developing therapeutics for breast cancer and rare diseases. The company specializes in creating potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) for HER2-positive breast cancer and Rett Syndrome. Additionally, DepYmed has developed a portfolio of novel small molecules with copper-chelating properties, which have potential applications in treating Wilson Disease and various cancers. The company collaborates with Cold Spring Harbor Laboratory to advance these therapeutic agents through preclinical development.

PainQx is a healthcare technology company that develops software to objectively measure pain in humans, with additional capabilities for veterinary applications. Its flagship PainQx System analyzes neural activity via EEG and processes the data with proprietary algorithms to produce a standardized pain score correlated to a patient's pain state. The platform enables clinicians and researchers to assess pain in patients who cannot reliably articulate it and to quantify pain-related outcomes for drug and device studies. Founded in 2015 and based in New York, PainQx offers its software on a pay-per-use or subscription basis and positions its system as a clinical assessment tool used by organizations to evaluate efficacy and side effects related to pain.

Paladin is a legal technology company founded in 2015 and based in New York, USA. The firm has developed a platform that connects attorneys with vetted pro bono opportunities, allowing legal professionals to engage in cases that align with their passions. By streamlining the process of creating, distributing, and managing pro bono matters, Paladin enables law firms, bar associations, and corporations to enhance their service delivery to low-income individuals. Additionally, the platform facilitates the tracking of lawyers' contributions and captures impact data, highlighting the positive effects of their efforts. Through its services, Paladin aims to enhance pro bono participation and support the legal community in addressing access to justice.

ENB Therapeutics develops small molecule inhibitors targeting the endothelin B receptor to enhance cancer immunotherapy. Founded in 2015, it aims to overcome drug resistance and reduce tumor growth, with its lead product ENB-001 granted Orphan Drug Designation by the FDA.

Mymee is a digital health company that empowers individuals with incurable rheumatic and neurological autoimmune diseases. Its platform identifies personalized triggers for symptoms through observational data analysis, providing tailored behavioral change plans supported by expert health coaches.

Marvel Genomics specializes in developing genetic tests to identify young children at risk of autism. Its proprietary diagnostic device uses sequencing technology and precise genetic tests, enabling early detection and intervention.